Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

A Systematic Review on Interferon Alpha-Induced Cognitive Impairment in Hepatitis C Patients

Author(s): Pallavi Kaushik, Mohd Ashif Khan*, Nidhi B. Agarwal and Aakriti Garg

Volume 18, Issue 2, 2023

Published on: 07 July, 2022

Page: [159 - 166] Pages: 8

DOI: 10.2174/1574886317666220428134931

Price: $65

Abstract

Objective: Interferon-alpha (IFN-α) is an important treatment modality for the hepatitis C virus (HCV). However, treatment with IFN-α is often associated with cognitive difficulties in HCV patients. Thus, this systematic review was performed to assess the effects of IFN-α on cognitive functioning in patients suffering from HCV.

Methods: Relevant literature was identified by performing a comprehensive literature search in major databases including PubMed, clinicaltrials.gov, and Cochrane Central using a combination of suitable keywords. We retrieved studies that were published from the start of each database until August 2021.

Results: Out of 210 articles, 73 studies were selected after removing the duplicates. In the first pass, 60 articles were excluded. Out of 13 full-text articles, only 5 articles qualified for qualitative analyses in the second pass. We observed conflicting results concerned with the use of IFN-α and the risk of neurocognitive impairment in HCV patients.

Conclusion: In conclusion, we have observed conflicting results regarding the impact of INF-α treatment on the cognitive functioning of patients suffering from HCV. Thus, there is an urgent need for an extensive study to evaluate the exact association between INF-αtherapy and cognitive functioning in HCV patients.

Keywords: Hepatitis C virus, hepatitis C patients, interferon-alpha, IFN-α, neurocognition, cognitive impairment.

« Previous Next »
[1]
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17(2): 107-15.
[http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x] [PMID: 21091831]
[2]
Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339(21): 1493-9.
[http://dx.doi.org/10.1056/NEJM199811193392102] [PMID: 9819447]
[3]
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4(6): 561-71.
[http://dx.doi.org/10.1001/archpsyc.1961.01710120031004]
[4]
Hassaan SH, Darwish AM, Khalifa H, et al. Assessment of cognitive functions and psychiatric symptoms in hepatitis C patients receiving pegylated interferon alpha and ribavirin: A prospective cohort study. Int J Psychiatry Med 2019; 54(6): 424-40.
[http://dx.doi.org/10.1177/0091217419858277] [PMID: 31219366]
[5]
Moriyama M, Arakawa Y. Treatment of interferon-alpha for chronic hepatitis C. Expert Opin Pharmacother 2006; 7(9): 1163-79.
[http://dx.doi.org/10.1517/14656566.7.9.1163] [PMID: 16732703]
[6]
Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006; 8(6): 907-22.
[http://dx.doi.org/10.1111/j.1462-5822.2006.00716.x] [PMID: 16681834]
[7]
Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102(8): 2992-7.
[http://dx.doi.org/10.1073/pnas.0408824102] [PMID: 15710891]
[8]
Kaneko N, Nakamura S, Sawamoto K. Effects of interferon-alpha on hippocampal neurogenesis and behavior in common marmosets. Mol Brain 2020; 13(1): 98.
[http://dx.doi.org/10.1186/s13041-020-00639-9] [PMID: 32590991]
[9]
Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82(2): 175-90.
[http://dx.doi.org/10.1016/j.jad.2004.04.002] [PMID: 15488246]
[10]
Caroleo B, Gallelli L, Staltari O, De Sarro G, Guadagnino V. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol. Intervirology 2008; 51(6): 407-9.
[http://dx.doi.org/10.1159/000205266] [PMID: 19258719]
[11]
Gallelli L, Guadagnino V, Caroleo B, Marigliano N, De Sarro GB, Izzi A. Bilateral skin ulceration after injection of Pegylated interferon-alpha-2b in a patient with chronic hepatitis C. Clin Drug Investig 2003; 23(9): 615-9.
[http://dx.doi.org/10.2165/00044011-200323090-00009] [PMID: 17535076]
[12]
Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9(6): 847-54.
[http://dx.doi.org/10.1017/S1355617703960048] [PMID: 14632243]
[13]
Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: An overview of cases in Japan. Psychiatry Clin Neurosci 1997; 51(4): 175-80.
[http://dx.doi.org/10.1111/j.1440-1819.1997.tb02579.x] [PMID: 9316160]
[14]
Scalori A, Apale P, Panizzuti F, et al. Depression during interferon therapy for chronic viral hepatitis: Early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12(5): 505-9.
[http://dx.doi.org/10.1097/00042737-200012050-00005] [PMID: 10833092]
[15]
Schaefer M, Schmidt F, Horn M, Schmid-Wendtner MH, Volkenandt M. Depression during treatment with interferon alpha. Psychosomatics 2004; 45(2): 176.
[http://dx.doi.org/10.1176/appi.psy.45.2.176]
[16]
Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18(11): 2316-26.
[http://dx.doi.org/10.1200/JCO.2000.18.11.2316] [PMID: 10829053]
[17]
Valentine AD, Meyers CA. Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. Psychosomatics 1995; 36(4): 418-9.
[http://dx.doi.org/10.1016/S0033-3182(95)71658-9]
[18]
Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31(6): 1207-11.
[http://dx.doi.org/10.1053/jhep.2000.7880] [PMID: 10827143]
[19]
Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012; 83(5): 495-502.
[http://dx.doi.org/10.1136/jnnp-2011-301779] [PMID: 22423117]
[20]
Haria M, Benfield P. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995; 50(5): 873-96.
[http://dx.doi.org/10.2165/00003495-199550050-00007] [PMID: 8586031]
[21]
Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20(17): 3703-18.
[http://dx.doi.org/10.1200/JCO.2002.03.052] [PMID: 12202672]
[22]
Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25(3): 283-91.
[http://dx.doi.org/10.1016/S0168-8278(96)80113-9] [PMID: 8895006]
[23]
Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9(4): 273-7.
[http://dx.doi.org/10.1055/s-2008-1040523] [PMID: 2690351]
[24]
Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157(6): 867-76.
[http://dx.doi.org/10.1176/appi.ajp.157.6.867] [PMID: 10831463]
[25]
Smith A, Tyrrell D, Coyle K, Higgins P. Effects of interferon alpha on performance in man: A preliminary report. Psychopharmacology 1988; 96(3): 414-6.
[http://dx.doi.org/10.1007/BF00216072] [PMID: 3146777]
[26]
Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25(1) (Suppl. 1): 39-47.
[PMID: 9482539]
[27]
Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41(5): 672-6.
[http://dx.doi.org/10.1212/WNL.41.5.672] [PMID: 2027482]
[28]
Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state. New Engl J Med 1999; 340(17): 1370.
[http://dx.doi.org/10.1056/NEJM199904293401716]
[29]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[30]
Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK. Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis. Rheumatol Int 2018; 38(11): 1999-2014.
[http://dx.doi.org/10.1007/s00296-018-4142-x] [PMID: 30159775]
[31]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[32]
Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): Results from a prospective study. Eur Psychiatry 2006; 21(3): 204-10.
[http://dx.doi.org/10.1016/j.eurpsy.2004.09.030] [PMID: 16632167]
[33]
Huckans M, Fuller B, Wheaton V, et al. A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res 2015; 78(2): 184-92.
[http://dx.doi.org/10.1016/j.jpsychores.2014.07.020] [PMID: 25219976]
[34]
Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005; 11(1): 16-22.
[http://dx.doi.org/10.1017/S1355617705050022] [PMID: 15686604]
[35]
Fontana RJ, Bieliauskas LA, Back-Madruga C, et al. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 2010; 105(7): 1551-60.
[http://dx.doi.org/10.1038/ajg.2010.3] [PMID: 20104219]
[36]
Rodrigue JR, Balistreri W, Haber B, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology 2011; 53(5): 1468-75.
[http://dx.doi.org/10.1002/hep.24248] [PMID: 21351116]
[37]
Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007; 45(5): 1154-63.
[http://dx.doi.org/10.1002/hep.21633] [PMID: 17465000]
[38]
Merimsky O, Chaitchik S. Neurotoxicity of interferon-alpha. Anticancer Drugs 1992; 3(6): 567-70.
[http://dx.doi.org/10.1097/00001813-199212000-00002] [PMID: 1288726]
[39]
Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism: Relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54(9): 906-14.
[http://dx.doi.org/10.1016/S0006-3223(03)00173-2] [PMID: 14573318]
[40]
Mendoza-Fernández V, Andrew RD, Barajas-López C. Interferon-alpha inhibits long-term potentiation and unmasks a long-term depression in the rat hippocampus. Brain Res 2000; 885(1): 14-24.
[http://dx.doi.org/10.1016/S0006-8993(00)02877-8] [PMID: 11121525]
[41]
Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression. J Psychiatry Neurosci 2004; 29(1): 11-7.
[PMID: 14719046]
[42]
Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: A review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(4): 731-46.
[http://dx.doi.org/10.1016/S0278-5846(01)00324-4] [PMID: 12188106]
[43]
Tagliapietra M, Monaco S. Neuroimaging findings in chronic Hepatitis C virus infection: Correlation with neurocognitive and neuropsychiatric manifestations. Int J Mol Sci 2020; 21(7): E2478.
[http://dx.doi.org/10.3390/ijms21072478] [PMID: 32252497]
[44]
Bladowska J, Pawłowski T, Fleischer-Stępniewska K, et al. Interferon-free therapy as the cause of white matter tracts and cerebral perfusion recovery in patients with chronic hepatitis C. J Viral Hepat 2019; 26(6): 635-43.
[http://dx.doi.org/10.1111/jvh.13069] [PMID: 30702208]

Rights & Permissions Print Cite
Article Metrics
39
2
© 2024 Bentham Science Publishers | Privacy Policy